Basic Information
| RNALocate ID: | RLID:11003622 |
| RNA Symbol: | hsa-miR-29b-2-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-29b-2-5p |
| RNA ID: | miRBase:MIMAT0004515 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23663360 |
| Tissue/Cell Line: | Plasma |
| Method: | Next-generation RNA sequencing |
| Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002585 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:11003623 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000592 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
| RLID-D:11001471 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-29b-2-5p | Oral squamous cell carcinoma | MNDR-E-MI-35168 |
| MNDR | hsa-miR-29b-2-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-35169 |
| MNDR | hsa-miR-29b-2-5p | Ovarian clear cell carcinoma | MNDR-E-MI-35170 |
| MNDR | hsa-miR-29b-2-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-35171 |
| MNDR | hsa-miR-29b-2-5p | Lymphoma | MNDR-E-MI-35172 |
| MNDR | hsa-miR-29b-2-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-35173 |
| MNDR | hsa-miR-29b-2-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-35174 |
| MNDR | hsa-miR-29b-2-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-35175 |
| MNDR | hsa-miR-29b-2-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-35176 |
| MNDR | hsa-miR-29b-2-5p | Her2-receptor positive breast cancer | MNDR-E-MI-35177 |
| MNDR | hsa-miR-29b-2-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-35178 |
| MNDR | hsa-miR-29b-2-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-35179 |
| MNDR | hsa-miR-29b-2-5p | Prostate cancer | MNDR-E-MI-35180 |
| MNDR | hsa-miR-29b-2-5p | Chronic lymphocytic leukemia | MNDR-E-MI-35181 |
| MNDR | hsa-miR-29b-2-5p | Alzheimer disease | MNDR-E-MI-35182 |
| MNDR | hsa-miR-29b-2-5p | Intracranial aneurysm | MNDR-E-MI-35183 |
| MNDR | hsa-miR-29b-2-5p | Esophageal carcinoma | MNDR-E-MI-35184 |
| MNDR | hsa-miR-29b-2-5p | Leukemia | MNDR-E-MI-35185 |
| MNDR | hsa-miR-29b-2-5p | Lung cancer | MNDR-E-MI-35186 |
| MNDR | hsa-miR-29b-2-5p | Parkinson disease | MNDR-E-MI-35187 |
| MNDR | hsa-miR-29b-2-5p | Breast cancer | MNDR-E-MI-35188 |
| MNDR | hsa-miR-29b-2-5p | Thyroid cancer | MNDR-E-MI-35189 |
| MNDR | hsa-miR-29b-2-5p | Pancreatic cancer | MNDR-E-MI-35190 |
| MNDR | hsa-miR-29b-2-5p | Melanoma | MNDR-E-MI-35191 |
| MNDR | hsa-miR-29b-2-5p | Rectum adenocarcinoma | MNDR-E-MI-35192 |
| MNDR | hsa-miR-29b-2-5p | Nephroblastoma | MNDR-E-MI-35193 |
| MNDR | hsa-miR-29b-2-5p | Colon cancer | MNDR-E-MI-35194 |
| MNDR | hsa-miR-29b-2-5p | Colon adenocarcinoma | MNDR-E-MI-35195 |
| MNDR | hsa-miR-29b-2-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-35196 |
| MNDR | hsa-miR-29b-2-5p | Prostate adenocarcinoma | MNDR-E-MI-35197 |
| MNDR | hsa-miR-29b-2-5p | Glioblastoma | MNDR-E-MI-35198 |
| MNDR | hsa-miR-29b-2-5p | Rhabdomyosarcoma | MNDR-E-MI-35199 |
| MNDR | hsa-miR-29b-2-5p | Osteosarcoma | MNDR-E-MI-35200 |
| MNDR | hsa-miR-29b-2-5p | Infarction middle cerebral artery | MNDR-E-MI-35201 |
| MNDR | hsa-miR-29b-2-5p | Gastric adenocarcinoma | MNDR-E-MI-35202 |
| MNDR | hsa-miR-29b-2-5p | Cervical squamous cell carcinoma | MNDR-E-MI-35203 |
| MNDR | hsa-miR-29b-2-5p | Lung squamous cell carcinoma | MNDR-E-MI-35204 |
| MNDR | hsa-miR-29b-2-5p | Lung adenocarcinoma | MNDR-E-MI-35205 |
| MNDR | hsa-miR-29b-2-5p | Ovarian carcinoma | MNDR-E-MI-35206 |
| MNDR | hsa-miR-29b-2-5p | Bladder urothelial carcinoma | MNDR-E-MI-35207 |
| MNDR | hsa-miR-29b-2-5p | Pancreatic adenocarcinoma | MNDR-E-MI-35208 |
| MNDR | hsa-miR-29b-2-5p | Carcinoma renal cell | MNDR-E-MI-35209 |
| MNDR | hsa-miR-29b-2-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-35210 |
| MNDR | hsa-miR-29b-2-5p | Renal clear cell carcinoma | MNDR-E-MI-35211 |
| MNDR | hsa-miR-29b-2-5p | Cholangiocarcinoma | MNDR-E-MI-35212 |
| MNDR | hsa-miR-29b-2-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-35213 |
| MNDR | hsa-miR-29b-2-5p | T acute lymphoblastic leukemia | MNDR-E-MI-35214 |
| MNDR | hsa-miR-29b-2-5p | Acute t cell leukemia | MNDR-E-MI-35215 |
| MNDR | hsa-miR-29b-2-5p | Adenoma | MNDR-E-MI-35216 |
| MNDR | hsa-miR-29b-2-5p | Hepatocellular carcinoma | MNDR-E-MI-35217 |
| MNDR | hsa-miR-29b-2-5p | Acute myelocytic leukemia | MNDR-E-MI-35218 |
| MNDR | hsa-miR-29b-2-5p | Colorectal cancer | MNDR-E-MI-35219 |
| MNDR | hsa-miR-29b-2-5p | Nasopharynx carcinoma | MNDR-E-MI-35220 |
| MNDR | hsa-miR-29b-2-5p | Nasopharyngeal cancer | MNDR-E-MI-35221 |
| MNDR | hsa-miR-29b-2-5p | Breast cancer her3+ negative | MNDR-E-MI-35222 |
| MNDR | hsa-miR-29b-2-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-35223 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | CASP3 | Homo sapiens | RR00278967 |
TOP